Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 877 to 883 of 883 entries
Sorted by: Best Match Show Resources per page
Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics.

Metabolites

Lima AR, Pinto J, Amaro F, Bastos ML, Carvalho M, Guedes de Pinho P.
PMID: 33808897
Metabolites. 2021 Mar 19;11(3). doi: 10.3390/metabo11030181.

Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent...

Cite
Lima AR, Pinto J, Amaro F, et al. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites. 2021;11(3)doi: 10.3390/metabo11030181.
Lima, A. R., Pinto, J., Amaro, F., Bastos, M. L., Carvalho, M., & Guedes de Pinho, P. (2021). Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites, 11(3), . https://doi.org/10.3390/metabo11030181
Lima, Ana Rita, et al. "Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics." Metabolites vol. 11,3 (2021). doi: https://doi.org/10.3390/metabo11030181
Lima AR, Pinto J, Amaro F, Bastos ML, Carvalho M, Guedes de Pinho P. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites. 2021 Mar 19;11(3). doi: 10.3390/metabo11030181. PMID: 33808897; PMCID: PMC8003702.
Copy Download .nbib Format: NLM
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?.

Blood advances

Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G.
PMID: 34525181
Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824.

Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is...

Cite
Tedeschi A, Frustaci AM, Mauro FR, et al. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?. Blood Adv. 2021;5(24):5490-5500doi: 10.1182/bloodadvances.2021004824.
Tedeschi, A., Frustaci, A. M., Mauro, F. R., Chiarenza, A., Coscia, M., Ciolli, S., Reda, G., Laurenti, L., Varettoni, M., Murru, R., Baratè, C., Sportoletti, P., Greco, A., Borella, C., Rossi, V., Deodato, M., Biagi, A., Zamprogna, G., Pelle, A. C., Lapietra, G., Vitale, C., Morelli, F., Cassin, R., Fresa, A., Cavalloni, C., Postorino, M., Ielo, C., Cairoli, R., Di Raimondo, F., Montillo, M., & Del Poeta, G. (2021). Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?. Blood advances, 5(24), 5490-5500. https://doi.org/10.1182/bloodadvances.2021004824
Tedeschi, Alessandra, et al. "Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?." Blood advances vol. 5,24 (2021): 5490-5500. doi: https://doi.org/10.1182/bloodadvances.2021004824
Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?. Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824. PMID: 34525181.
Copy Download .nbib Format: NLM
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Nature reviews. Gastroenterology & hepatology

Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L.
PMID: 34453143
Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):857-873. doi: 10.1038/s41575-021-00492-8. Epub 2021 Aug 27.

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations...

Cite
Olivera PA, Zuily S, Kotze PG, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(12):857-873doi: 10.1038/s41575-021-00492-8.
Olivera, P. A., Zuily, S., Kotze, P. G., Regnault, V., Al Awadhi, S., Bossuyt, P., Gearry, R. B., Ghosh, S., Kobayashi, T., Lacolley, P., Louis, E., Magro, F., Ng, S. C., Papa, A., Raine, T., Teixeira, F. V., Rubin, D. T., Danese, S., & Peyrin-Biroulet, L. (2021). International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology, 18(12), 857-873. https://doi.org/10.1038/s41575-021-00492-8
Olivera, Pablo A, et al. "International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease." Nature reviews. Gastroenterology & hepatology vol. 18,12 (2021): 857-873. doi: https://doi.org/10.1038/s41575-021-00492-8
Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):857-873. doi: 10.1038/s41575-021-00492-8. Epub 2021 Aug 27. PMID: 34453143; PMCID: PMC8395387.
Copy Download .nbib Format: NLM
Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2.

bioRxiv : the preprint server for biology

Mugnai ML, Templeton C, Elber R, Thirumalai D.
PMID: 33299995
bioRxiv. 2020 Dec 01; doi: 10.1101/2020.11.30.405340.

Severe acute respiratory syndrome (SARS) and novel coronavirus disease (COVID-19) are caused by two closely related beta-coronaviruses, SARS-CoV and SARS-CoV-2, respectively. The envelopes surrounding these viruses are decorated with spike proteins, whose receptor binding domains (RBDs) initiate invasion by...

Cite
Mugnai ML, Templeton C, Elber R, et al. Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2. bioRxiv. 2020;doi: 10.1101/2020.11.30.405340.
Mugnai, M. L., Templeton, C., Elber, R., & Thirumalai, D. (2020). Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.11.30.405340
Mugnai, Mauro L, et al. "Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.11.30.405340
Mugnai ML, Templeton C, Elber R, Thirumalai D. Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2. bioRxiv. 2020 Dec 01; doi: 10.1101/2020.11.30.405340. PMID: 33299995; PMCID: PMC7724663.
Copy Download .nbib Format: NLM
Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.

Journal of Crohn's & colitis

Ungar B, Malickova K, Hanžel J, Abu Arisha M, Paul S, Rocha C, Ben Shatach Z, Abitbol CM, Haj Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben Horin S.
PMID: 33837762
J Crohns Colitis. 2021 Oct 07;15(10):1707-1719. doi: 10.1093/ecco-jcc/jjab067.

BACKGROUND: Real life data regarding pharmacokinetics of vedolizumab in patients needing dose optimisation are scarce. We set to examine whether pre-optimisation vedolizumab levels associate with therapy outcomes and which mechanisms explain the associations.METHODS: A multicentre observational study assessed the...

Cite
Ungar B, Malickova K, Hanžel J, et al. Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms. J Crohns Colitis. 2021;15(10):1707-1719doi: 10.1093/ecco-jcc/jjab067.
Ungar, B., Malickova, K., Hanžel, J., Abu Arisha, M., Paul, S., Rocha, C., Ben Shatach, Z., Abitbol, C. M., Haj Natour, O., Selinger, L., Yavzori, M., Fudim, E., Picard, O., Shoval, I., Eliakim, R., Kopylov, U., Magro, F., Roblin, X., Chowers, Y., Drobne, D., Lukas, M., & Ben Horin, S. (2021). Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms. Journal of Crohn's & colitis, 15(10), 1707-1719. https://doi.org/10.1093/ecco-jcc/jjab067
Ungar, Bella, et al. "Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms." Journal of Crohn's & colitis vol. 15,10 (2021): 1707-1719. doi: https://doi.org/10.1093/ecco-jcc/jjab067
Ungar B, Malickova K, Hanžel J, Abu Arisha M, Paul S, Rocha C, Ben Shatach Z, Abitbol CM, Haj Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben Horin S. Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms. J Crohns Colitis. 2021 Oct 07;15(10):1707-1719. doi: 10.1093/ecco-jcc/jjab067. PMID: 33837762.
Copy Download .nbib Format: NLM
Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

F M, D M, M P, B A, P L, I R, Ht S, P M, I M, A V, J C, J M, J R, C E, P S, F P, L C, M S, S D, C A, J A, S D, L PB, Cc D.
PMID: 34896644
Clin Gastroenterol Hepatol. 2021 Dec 09; doi: 10.1016/j.cgh.2021.12.004. Epub 2021 Dec 09.

BACKGROUND AND AIMS: Subclinical intestinal inflammation is common in Crohn's disease (CD). We aimed to explore its impact in the disease progression of infliximab-treated patients and the usefulness of fecal calprotectin (FC) and C-reactive protein (CRP) as surrogate minimally...

Cite
F M, D M, M P, et al. Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.12.004.
F, M., D, M., M, P., B, A., P, L., I, R., Ht, S., P, M., I, M., A, V., J, C., J, M., J, R., C, E., P, S., F, P., L, C., M, S., S, D., C, A., J, A., S, D., L, P. B., Cc, D. (2021). Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.12.004
F, Magro, et al. "Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.12.004
F M, D M, M P, B A, P L, I R, Ht S, P M, I M, A V, J C, J M, J R, C E, P S, F P, L C, M S, S D, C A, J A, S D, L PB, Cc D. Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clin Gastroenterol Hepatol. 2021 Dec 09; doi: 10.1016/j.cgh.2021.12.004. Epub 2021 Dec 09. PMID: 34896644.
Copy Download .nbib Format: NLM
Early survey with bibliometric analysis on machine learning approaches in controlling COVID-19 outbreaks.

PeerJ. Computer science

Chiroma H, Ezugwu AE, Jauro F, Al-Garadi MA, Abdullahi IN, Shuib L.
PMID: 33816964
PeerJ Comput Sci. 2020 Nov 23;6:e313. doi: 10.7717/peerj-cs.313. eCollection 2020.

BACKGROUND AND OBJECTIVE: The COVID-19 pandemic has caused severe mortality across the globe, with the USA as the current epicenter of the COVID-19 epidemic even though the initial outbreak was in Wuhan, China. Many studies successfully applied machine learning...

Cite
Chiroma H, Ezugwu AE, Jauro F, et al. Early survey with bibliometric analysis on machine learning approaches in controlling COVID-19 outbreaks. PeerJ Comput Sci. 2020;6:e313doi: 10.7717/peerj-cs.313.
Chiroma, H., Ezugwu, A. E., Jauro, F., Al-Garadi, M. A., Abdullahi, I. N., & Shuib, L. (2020). Early survey with bibliometric analysis on machine learning approaches in controlling COVID-19 outbreaks. PeerJ. Computer science, 6e313. https://doi.org/10.7717/peerj-cs.313
Chiroma, Haruna, et al. "Early survey with bibliometric analysis on machine learning approaches in controlling COVID-19 outbreaks." PeerJ. Computer science vol. 6 (2020): e313. doi: https://doi.org/10.7717/peerj-cs.313
Chiroma H, Ezugwu AE, Jauro F, Al-Garadi MA, Abdullahi IN, Shuib L. Early survey with bibliometric analysis on machine learning approaches in controlling COVID-19 outbreaks. PeerJ Comput Sci. 2020 Nov 23;6:e313. doi: 10.7717/peerj-cs.313. eCollection 2020. PMID: 33816964; PMCID: PMC7924648.
Copy Download .nbib Format: NLM
Showing 877 to 883 of 883 entries